Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
暂无分享,去创建一个
P. Sharma | M. Konopleva | M. Andreeff | J. Blando | J. Allison | H. Kantarjian | G. Garcia-Manero | J. Cortes | K. Patel | T. Kadia | E. Jabbour | N. Daver | C. Dinardo | S. Kornblau | C. Bueso-Ramos | J. Ning | N. Pemmaraju | S. Basu | J. Jorgensen | F. Ravandi‐Kashani | G. Nogueras-Gonzalez | S. Pierce | P. Boddu | M. Alfayez | Tauna Gordon | W. Flores | Zainab Alhamal | F. Ravandi-kashani | F. Ravandi-Kashani | C. Bueso‐Ramos | Sreyashi Basu | Padmanee Sharma
[1] Peripheral , 2020, Definitions.
[2] P. Sharma,et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes , 2018, Leukemia.
[3] Tae Kon Kim,et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. , 2018, Blood advances.
[4] M. Konopleva,et al. Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.
[5] A. Letai,et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.
[6] Mithat Gonen,et al. Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[7] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[8] P. Sharma,et al. Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity , 2017 .
[9] A. Goldberg,et al. Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies , 2017 .
[10] A. Lesokhin,et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. , 2017, Blood.
[11] M. Konopleva,et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia , 2017, Cancer.
[12] Joe Y. Chang,et al. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells , 2016, Clinical Cancer Research.
[13] M. Liedtke,et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[14] F. Hodi,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[15] H. Ditzel,et al. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[16] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[17] R. Larson,et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.
[18] S. Zhang,et al. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia , 2014, Cancer science.
[19] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[20] S. Parmar,et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents , 2013, Leukemia.
[21] R. Davis,et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[22] Peter A. Jones,et al. Alterations of immune response of non-small cell lung cancer with Azacytidine , 2013, Oncotarget.
[23] S. Isom,et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML) , 2013, Annals of Hematology.
[24] C. Schumann,et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Lancet,et al. A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population , 2010 .
[26] D. Munn,et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. , 2010, Blood.
[27] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[29] H. Xu,et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia , 2009, Clinical and experimental immunology.
[30] J. Gribben,et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. , 2009, Blood.
[31] T. Gajewski,et al. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. , 2009, Blood.
[32] R. Berger,et al. Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.
[33] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[34] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P F Thall,et al. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. , 1998, Statistics in medicine.